CSIMarket Company Name, Ticker, Competitors, else..
 
Bioventus Inc   (NASDAQ: BVS)
 
Price: $13.8300 $-0.24 -1.706%
Day's High: $14.079999923706055 Week Perf: 1.17 %
Day's Low: $ 13.60 30 Day Perf: -2.09 %
Volume (M): 478,616 52 Wk High: $ 15.89
Volume (M$): $ 0 52 Wk Avg: $9.19
Open: $14.04 52 Wk Low: $6.26



 Market Capitalization (Millions $) 980
 Shares Outstanding (Millions) 71
 Employees 940
 Revenues (TTM) (Millions $) 581
 Net Income (TTM) (Millions $) 61
 Cash Flow (TTM) (Millions $) 13
 Capital Exp. (TTM) (Millions $) 3

Business Description


Bioventus Inc. is a global medical technology company that focuses on orthobiologics and orthopedic solutions. The company develops and manufactures innovative products designed to help patients with musculoskeletal conditions and injuries. These products include treatments for osteoarthritis, joint pain, cartilage damage, and bone fractures. Bioventus has a diverse portfolio of products, including surgical and non-surgical options, as well as drugs and devices. The company is committed to improving patient outcomes and quality of life through its advanced orthopedic solutions.


   Company Address: 4721 Emperor Boulevard Durham 27703 NC
   Company Phone Number: 474-6700   Stock Exchange / Ticker: NASDAQ BVS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
EW   -4.35%    
GMED   -7.78%    
ISRG   -3.69%    
MDT        1.1% 
SYK   -12.67%    
TFX   -3.56%    
• View Complete Report
   



Product Service News

Bioventus Takes Strategic Leap Offloading Rehabilitation Business to Focus on Core Innovations

Published Thu, Jan 2 2025 2:40 PM UTC

In a significant shift within the landscape of HealthTech, Bioventus Inc. (Nasdaq: BVS), a renowned player in the sector of active healing innovations, has completed the divestiture of its Advanced Rehabilitation business to Accelmed Partners. This strategic maneuver, finalized on January 2, 2025, represents the culmination of a decision previously announced on October 1, 20...
Stock Market Announcement

Bioventus Inc Divests Advanced Rehabilitation Business to Fortify Financial Position Amid Strategic Realignment

Published Tue, Oct 1 2024 1:01 PM UTC

Bioventus Inc. Divests Advanced Rehabilitation Business to Fortify Financial Position Amid Strategic RealignmentIn a pivotal move to streamline operations and enhance its financial stability, Bioventus Inc. (Nasdaq: BVS), a prominent force in active healing and rehabilitation technologies, has announced the sale of its Advanced Rehabilitation business, a division of its subs...
Financing Agreement

Bioventus Enhances Financial and Operational Flexibility through Amendment with Credit Agreement Lenders

Published Thu, Jan 18 2024 9:15 PM UTC



Bioventus Inc. (Bioventus), a renowned global leader in active healing innovations, recently announced a significant milestone in its financial and operational strategies. The company entered into Amendment No. 5 to its Credit and Guaranty Agreement, paving the way for enhanced flexibility and opportunities for growth. With this amendment, Bioventus aims to solidif...
Shares

Bioventus Strengthens Leadership with Inducement Equity Awards to Newly Appointed CEO

Published Fri, Jan 12 2024 9:15 PM UTC



Durham-based global leader in innovations for active healing, Bioventus Inc. (Nasdaq: BVS), recently announced the issuance of inducement equity awards to Robert (Rob) Claypoole, who has been appointed as the President and Chief Executive Officer, as well as the Principle Executive Officer of the company. This move marks an important step forward for Bioventus, as ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 17.96
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1.69
Price to Sales (Expected) -
Price to Book 3.53
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.19
Working Capital Ratio 1.67
Leverage Ratio (MRQ) 1.61
Total Debt to Equity 0.9
Interest Coverage (TTM) 5.65
Debt Coverage (TTM) 0.35

Per Share Current
Earnings (TTM) 0.77 $
Revenues (TTM) 8.2 $
Cash Flow (TTM) 0.18 $
Cash 0.42 $
Book Value 3.92 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 618,198
Net Income per Employee (TTM) 65,399
Receivable Turnover Ratio (TTM) 4.49
Inventory Turnover Ratio (TTM) 2.14
Asset Turnover Ratio (TTM) 0.86

Profitability Ratios Current
Gross Margin (MRQ) 68.97 %
Operating Margin (MRQ) 12.48 %
Net Margin (MRQ) 23.63 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) 9.09 %
Return On Investment (TTM) 10.86 %
Return On Equity (TTM) 25.96 %
Dividend Yield -
Pay out Ratio (TTM) -



Bioventus Inc's Segments
International Segment    10.65 % of total Revenue
Surgical Solutions    8 % of total Revenue
Restorative Therapies    3.8 % of total Revenue
United States    163.77 % of total Revenue
Non-US    22.44 % of total Revenue
U.S.    163.77 % of total Revenue
International    22.44 % of total Revenue

  Bioventus Inc Outlook

On March 12 2024 the Bioventus Inc provided following guidance

On March 12, 2024, Bioventus Inc. (Nasdaq: BVS), known for its global leadership in developing innovations for active healing, revealed its financial performance for the fourth quarter and full year of 2023. The company also shared its financial projections for the entirety of 2024.

Based on the figures released by Bioventus, the company has shown positive growth and strong financial performance throughout the year 2023. The financial results for the fourth quarter and full year of 2023, which ended on December 31st, indicate that Bioventus has successfully maintained its position as a global leader in active healing solutions.

Moreover, Bioventus has set ambitious financial targets for the yea...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.